Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pulmonary diffusing capacity measured by NO/CO transfer in Tunisian boys

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lung compartment analysis assessed from N2 multiple-breath washout in children with cystic fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Oral and anal carriage of Neisseria meningitidis among sexually active HIV-infected men who have sex with men in Denmark 2014-15

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Omics-based tracking of Pseudomonas aeruginosa persistence in "eradicated" cystic fibrosis patients.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Isoniazidinduceret toksisk hepatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: The present study was performed to explore dosing regimens of colistin in patients of cystic fibrosis (CF) with Pseudomonas aeruginosa chronic biofilm lung infection.

METHODS: Ten CF patients were involved. One dose colistimethate sodium (CMS) of 6 MIU (million international units) and 9 MIU were administered by intravenous infusion over 45 and 90 min. Venous blood was collected at different time points after the infusion of CMS. Pharmacokinetic parameters of colistin were calculated. Minimum inhibitory concentration for planktonic P. aeruginosa, minimum biofilm inhibitory concentration and minimum biofilm eradication concentration of P. aeruginosa were determined. Monte Carlo simulation was performed to determine the clinical probability of target attainment of different dosing regimens of colistin in CF patients.

RESULTS: For 90 min (6 MIU), 45 min (6 MIU), and 45 min (9 MIU) intravenous infusion of colistin, Cmax was 8.9 ± 1.8, 15 ± 5.5, and 31.7 ± 5.3 μg/mL, respectively; Tmax was 1.2 ± 0.4, 0.7 ± 0.2, and 0.8 ± 0.2 h, respectively; AUCtot were 31 ± 3.8, 34 ± 10, and 135 ± 31mg · h/L, respectively; t1/2 was 2.1 ± 0.4, 2 ± 0.3, and 3.3 ± 0.4 h, respectively. MBIC and MBEC of colistin on biofilms at 24 h period treatment were 16-128 μg/mL for non-mucoid and mucoid biofilms of P. aeruginosa. For 90 min (6 MIU), 45 min (6 MIU) and 45 min iv infusion (9 MIU) with one dose colistin, PTA was 49.8%, 53.8%, 99.4% for planktonic infection, and 11.3%, 14.6%, 65.3%, respectively for biofilm infection.

CONCLUSIONS: colistin treatment using 45 min iv infusion is better than 90 min iv infusion in this study. Colistin dosage of 9 MIU is better than 6 MIU on both planktonic and biofilm infections of P. aeruginosa in this study.

Original languageEnglish
JournalPediatric Pulmonology
Volume54
Issue number5
Pages (from-to)575-580
Number of pages6
ISSN8755-6863
DOIs
Publication statusPublished - May 2019

ID: 59045512